evaluation of the efficacy and the safety of intralesional cidofovir for recurrent laryngeal papillomatosis
Not Applicable
Recruiting
- Conditions
- human papillomavirus positive recurrent laryngeal papillomatosis
- Registration Number
- JPRN-UMIN000010967
- Lead Sponsor
- Department of Otorhinolaryngology, Head and Neck Surgery, Yokohama City University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
Not provided
Exclusion Criteria
renal dysfunction
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Tumor reduction / disappearance rate and time, adverse events
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie cidofovir's antiviral activity against HPV in recurrent laryngeal papillomatosis?
How does intralesional cidofovir compare to standard-of-care treatments like imiquimod for HPV-positive RLP recurrence rates?
Which biomarkers (e.g., p16, viral load) correlate with response to cidofovir in JPRN-UMIN000010967 trial participants?
What are the long-term safety profiles and management strategies for intralesional cidofovir in laryngeal papillomatosis patients?
Are there synergistic effects of combining cidofovir with other antiviral agents (e.g., ganciclovir) for HPV-driven RLP treatment?